MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Azzi, M.
Right arrow Articles by Bouvier, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Azzi, M.
Right arrow Articles by Bouvier, M.

Vol. 60, Issue 5, 999-1007, November 2001


Allosteric Effects of G Protein Overexpression on the Binding of beta -Adrenergic Ligands with Distinct Inverse Efficacies

Mounia Azzi, Graciela Piñeyro, Stéphanie Pontier, Stéphane Parent,1 Hervé Ansanay, and Michel Bouvier

Département de Biochimie and le Groupe de Recherches sur le Système Nerveux Autonome, Université de Montréal, Montréal, Québec, Canada

    Abstract
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Allosteric models of G protein-coupled receptors predict that G protein influences the spontaneous isomerization between inactive (R) and active (R*) conformations. Since inverse agonists have been proposed to preferentially bind to the inactive and uncoupled form(s), changes in the G protein content should influence the binding properties of these ligands. To test this hypothesis, we systematically assessed the effect of G proteins on the binding of beta 2-adrenergic ligands with distinct levels of inverse efficacy. Recombinant baculoviruses encoding the human beta 2-adrenoreceptor (beta 2AR) were expressed alone or in combination with G protein subunits in Sf9 cells. Coexpression with the G protein alpha sbeta 1gamma 2 did not influence the relative efficacy of the ligands to inhibit the adenylyl cyclase but induced considerable decrease in number of sites detected by [3H]ICI 118551, [3H]propranolol, and 125I-cyanopindolol. This loss was proportional to the inverse efficacy of the ligand used as the radiotracer in the assay. The addition of Gpp(NH)p inhibited the effects of G protein overexpression indicating that the G proteins acted allosterically. Consistent with this notion, Western blot analysis revealed that coexpression with the G proteins was not accompanied by a loss of immunoreactive beta 2AR. Such allosteric effects of the G proteins were also observed in mammalian cells expressing endogenous level of G proteins indicating that the phenomenon is not unique to overexpression systems. Taken together, these results demonstrate that the apparent receptor number detected by radiolabeled inverse agonists is affected by the content in G proteins as a result of their influence on R/R* isomerization.

    Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Traditionally, G protein-coupled receptors (GPCR) were considered to rest in an inactive conformation under basal conditions, requiring the presence of an agonist to undergo the necessary changes leading to activation and therefore receptor/G protein coupling. In this occupational interpretation of receptor activation, antagonists were believed to lack intrinsic activity, occupying the receptor without inducing changes in G protein coupling. More recently, a growing body of evidence has challenged this notion. Indeed, following the development of receptor mutants that show constitutive (ligand-independent) activity and that of overexpression systems that revealed spontaneous agonist-independent activity even for wild-type GPCRs, the notion that some ligands (inverse agonists) may inhibit constitutive/spontaneous activity has emerged (for review, see Kenakin, 1996; Bond and Bouvier, 1998). As traditionally described for agonists, inverse agonists were also found to display different efficacies, ranging from almost neutral antagonism to full inverse agonism (Chidiac et al., 1994; Leeb-Lundberg et al., 1994; Labrecque et al., 1995; Gardella et al., 1996; Mullaney et al., 1996; Smith et al., 1996; Lee et al., 1997; Jansson et al., 1998). Based on the interpretation of these studies, numerous thermodynamic models proposing the allosteric interconversion of receptors between active and inactive states have been proposed (Samama et al., 1993; Kenakin, 1995; Weiss et al., 1996; Leff and Scaramellini, 1998).

According to the two-state model (Karlin, 1967; Colquhoun, 1973; Thron, 1973; Leff, 1995), agonist-independent activation of GPCRs is believed to reflect the spontaneous isomerization of the receptor between inactive (R) and active (R*) conformations, with the equilibrium under native conditions shifted toward R for most receptors. In this model, agonists are considered as preferentially binding and stabilizing R* (thus leading to activation) whereas inverse agonists by binding to R would inhibit the system. Neutral antagonists that do not discriminate between the two conformers would leave the equilibrium between the two isomers unchanged. Furthermore, receptors are known to interact with a transducer G protein and thus to exist in an uncoupled (R) and a coupled (RG) conformation. Based on the thermodynamic description of the ternary complex model and its extended form (De Lean et al., 1980; Lefkowitz et al., 1993; Samama et al., 1993), R* would spontaneously couple to the G protein whereas the interaction between inactive R and G would not be favored. Furthermore, the activated R* state has been shown to be stabilized by the guanine nucleotide-free G protein alpha -subunit (Seifert et al., 1998), and it is this activated/coupled form (R*G) of the receptor that displays the highest affinity for agonists. On the other hand, GTP analogs are considered to decrease the affinity of agonists for their cognate receptors by promoting receptor/G protein dissociation (De Lean et al., 1980; Kenakin, 1996).

In keeping with the prediction of the two-state allosteric model, it is expected that any condition that would change the equilibrium between R and R* must have an impact on receptor activity and ligand affinity simultaneously. In keeping with this prediction, it has been shown for many GPCRs that an increase in constitutive activity is linked to an increase in apparent agonist affinity (Cotecchia et al., 1990; Kjelsberg et al., 1992; Ren et al., 1993; Samama et al., 1993) and that such increases in binding affinity correlate well with the pharmacological efficacy of agonists (Samama et al., 1993). On the other hand, if as predicted by the two-state model, inverse agonists bind preferentially to the inactive form of the receptor, the apparent affinity of these drugs is expected to decrease in conditions that shift the equilibrium toward R* (Gether and Kobilka, 1998). Although changes in inverse agonist binding have been reported in some studies in which R/R* or R/RG equilibrium was manipulated (Barker et al., 1994; Bouaboula et al., 1997; Francken et al., 2000), no study has systematically examined the prediction of the two-state model on inverse agonist binding properties.

The aim of the present study was to directly assess the effect of promoting R*G formation on inverse agonist binding. For this purpose, we took advantage of the baculovirus/Spodoptera frugiperda 9 (Sf9) cell expression system, which has extensively been used to reconstitute the interactions between specific GPCRs and their cognate G proteins (Butkerait et al., 1995; Grunewald et al., 1996; Barr and Manning, 1997; Barr et al., 1997; Francken et al., 2000). Overexpression of Galpha sbeta 1gamma 2 led to a significant reduction of inverse agonist binding to the human beta 2AR expressed in the same cells. In conformity with the two-state model, the extent of the changes in inverse agonist binding was proportional to inverse efficacy of the ligands tested. Similar binding decreases were also observed when a constitutively active beta 2AR mutant was used, indicating that stabilization of R* through either constitutively activating mutation or overexpression of G protein has similar effects on inverse agonist binding properties.

    Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Baculoviruses. The recombinant c-myc beta 2AR human baculoviruses was constructed by Mouillac et al. (1992). Recombinant baculoviruses encoding the different G protein subunits (rat alpha s short form, rat alpha i1, human alpha q, bovine beta 1, bovine gamma 2) and beta -galactosidase were obtained from Biosignal (Montréal, Québec). Those encoding the constitutively active mutant beta 2AR were kindly provided by Dr. B. K. Kobilka (HHMI, Stanford University Medical School, CA).

Cell Culture and Baculovirus Infection. Sf9 cells were cultured as monolayers in T flasks as described previously (Chidiac et al., 1996). Cells (at a density of 1-2 × 106 cells/ml) were infected with c-myc beta 2AR or constitutively active mutant beta 2AR encoding baculovirus at a multiplicity of infection (m.o.i.) of 1. For the coexpression of multiple Galpha - (Galpha s, Galpha i1, and Galpha q), Gbeta 1-, and Ggamma 2-subunits, an m.o.i. of 2 was used for each virus. The total m.o.i. was maintained at 8 in all infections by using the appropriate amount of beta -galactosidase virus. At 48-h postinfection, cells were harvested by centrifugation, washed twice with ice-cold phosphate-buffered saline (PBS), and directly used for membrane preparation. HEK293s cells stably expressing the beta 2AR were grown as monolayers in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 1 mM glutamine, 500 units/ml penicillin, and 500 units/ml streptomycin.

Membrane Preparation. Cells were resuspended and lysed under hypotonic conditions (5 mM Tris-HCl, pH 7.4, 2 mM EDTA, 5 µg/ml leupeptine, 5 µg/ml soybean trypsin inhibitor, and 10 µg/ml benzamidine) and homogenized with a polytron homogenizer (Ultra-Turrax; Janke and Kunkel, Staufen, Germany) for 5 s. Homogenates were centrifuged at 500g for 5 min at 4°C, and the resulting supernatant fraction was centrifuged at 25,000g for 20 min at 4°C. The membrane pellets were washed twice in the same buffer and centrifuged under the same conditions. The membrane pellet was finally resuspended in 75 mM Tris-HCl, pH 7.4, containing 5 mM MgCl2, 2 mM EDTA, and protease inhibitors as in the lysis buffer. The membranes were immediately used for adenylyl cyclase activity and radioligand binding assay or frozen at -80°C for Western blot analysis. Protein content in membrane preparation was estimated with the Bradford protein assay (Bradford, 1976) using the Bio-Rad kit. Bovine serum albumin was used as a standard.

Adenylyl Cyclase Activity. Membrane adenylyl cyclase activity was performed according to the method of Salomon et al. (1974). Briefly, 5 µg of membrane protein was incubated in the absence or presence of various concentrations of beta 2AR ligands with 0.12 mM ATP, 106 cpm [alpha -32P]ATP/assay (NEN Mandel), 0.1 mM cAMP, 53 µM GTP, 2.7 mM phosphoenolpyruvate, 0.1 mM isobutylmethylxanthine, 1 unit of myokinase, and 0.2 unit of pyruvate kinase, in a total volume of 50 µl. The samples were incubated at 37°C for 15 min, and the reaction was stopped by addition of 1 ml of a cold solution containing 0.4 mM ATP, 0.3 mM cAMP, and [3H]cAMP (25,000 cpm). cAMP was isolated by sequential chromatography using a Dowex gel followed by aluminum oxide.

Radioligand Binding Assay. Radioligand binding assays were performed essentially as described previously (Chidiac et al., 1996). Briefly, 1 to 3 µg of membrane proteins were incubated in a total volume of 0.5 ml in a buffer containing 75 mM Tris-HCl, pH 7.4, 5 mM MgCl2, 2 mM EDTA, protease inhibitors, and varying concentrations of the different radioligands tested: 125I-cyanopindolol (NEN Mandel), [3H]propranolol (NEN Mandel), or [3H]ICI 118551 (Tocris Cookson, St. Louis, MO). For single-point binding analysis, saturating concentrations of each ligand were used: 250 pM, 6 nM, and 8 nM for 125I-cyanopindolol, [3H]propranolol, and [3H]ICI 118551, respectively. Nonspecific binding was estimated in the presence of 10 µM alprenolol (Sigma, St. Louis, MO). Binding reactions were incubated at room temperature for 60 min for [3H]propranolol and 90 min for 125I-cyanopindolol and [3H]ICI 118551 and were terminated by rapid filtration through glass fiber (GF/C) filters (Whatman, Maidstone, UK) with ice-cold 25 mM Tris-HCl, pH 7.4. The experiments with Gpp(NH)p were performed with a concentration of 100 µM in the binding assay.

Western Blot Analysis. Membranes from Sf9 cells expressing the beta 2AR and different G protein subunits were reduced in Laemmli's sample buffer (Laemmli, 1970) and 5 and 10 µg of proteins were subjected to SDS-polyacrylamide gel electrophoresis (PAGE). Proteins were then transferred to nitrocellulose membrane (Xymotech) and probed for 1 h at room temperature with a mouse anti-c-myc monoclonal antibody (9E10, 1:2,000), a rabbit anti-beta 2AR polyclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA; 1:10,000), and rabbit anti-Gs, Gi, or Gq polyclonal antibodies (Santa Cruz Biotechnology, Inc.; 1:5,000). The first antibody was revealed with a horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG (Amersham Pharmacia Biotech, Piscataway, NJ; 1:20,000) and chemiluminescence using Renaissance plus kit (NEN Mandel). To ensure that the intensity of the signal was directly proportional to the amount of receptor protein loaded, serial dilutions of each membrane preparation were analyzed.

Flow Cytometry. The flow cytometry was performed as previously described (Morello et al., 2000). Briefly, Sf9 cells were permeabilized in PBS containing 0.15% Triton, fixed with 3% paraformaldehyde, and subsequently incubated with anti-beta 2AR (Santa Cruz Biotechnology, Inc.) antibody for 1 h at room temperature. The cells were then washed with PBS and incubated with phycoerythrin-conjugated goat anti-rabbit antibody (Immunotech, Westbrook, ME) for 1 h at room temperature. The cells were washed in PBS and analyzed on a FACS caliber Becton-Dickson flow cytometer (BD Immunocytometry Systems, San Jose, CA) set up to detect phycoerythrin fluorescence (585 ± 21 nm). For each sample, 10,000 cells were analyzed.

Data Analysis. For adenylyl cyclase assay, the data were calculated as picomoles of cAMP produced per minute per milligram of proteins and were expressed as percentage of control. Dose-response curves and saturation experiments were analyzed by nonlinear regression using the Prism program (GraphPad Software, San Diego, CA). EC50 values were derived from the curves. Maximal efficacies of each drug were determined as previously defined (Chidiac et al., 1994). For each set of data, the efficacy of the most inhibitory ligand, ICI 118551, was set at -1. Bmax and Kd values of the radioligand and IC50 values of inhibitors were derived from the curve fitting. Statistical analyses were performed using the Student's t test. p < 0.05 was considered statistically significant.

    Results
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

In an effort to systematically test the hypothesis that inverse agonists bind with higher affinity to the inactive/uncoupled forms of the receptor (R), we assessed the influence of G protein overexpression and constitutive activation of the beta 2AR in direct radioligand binding experiments. For this purpose, the relative efficacy of commonly used beta 2AR radioligands was first assessed in membranes from Sf9 cells expressing a high copy number of the human beta 2AR (8.43 ± 1.76 pmol/mg of protein). As shown in Fig. 1, ICI 118551, propranolol, and cyanopindolol were found to be inverse agonists because they inhibited the basal adenylyl cyclase activity by 48, 34, and 23%, respectively. The level of adenylyl cyclase activity, detected at the highest ICI 118551 concentrations, was undistinguishable from that observed in cells that did not express the receptor (data not shown), and thus an efficacy of -1 (full inverse agonist) was attributed to this compound. The inverse efficacies of cyanopindolol and propranolol were expressed relative to that of ICI 118551 (Table 1).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 1.   Inhibition of spontaneous adenylyl cyclase activity in membranes derived from Sf9 cells expressing the human beta 2AR. Adenylyl cyclase activity was determined as described under Materials and Methods in the presence of increasing concentrations (10-12-10-4 M) of cyanopindolol (black-diamond ), propranolol (black-square), or ICI 118551 (black-triangle). Values are expressed as percentage of ligand-independent (basal) activity and presented as the means ± S.E.M. of five to six independent experiments. Basal adenylyl cyclase activity ranged from 15.5 to 36.8 pmol of cAMP/mg of protein/min in these experiments. Mean EC50 and maximum inhibition values are summarized in Table 1.


                              
View this table:
[in this window]
[in a new window]
 
TABLE 1
Inverse efficacies and potencies of different beta 2AR ligands assessed in membranes expressing the beta 2AR alone or in combination with Galpha sbeta 1gamma 2

Einv and EC50 values were determined as described under Materials and Methods. Data shown represent the means of n independent experiments performed in duplicate. The efficacies of cyanopindolol and propranolol were scaled with ICI 118551 efficacy set at -1.00. Numbers into brackets represent the minimum and maximum for each condition.

Coexpression of the beta 2AR with Galpha sbeta 1gamma 2 promoted a 2.9-fold increase in the basal adenylyl cyclase activity (60 ± 0.6 versus 175 ± 13 pmol/mg of protein/min for membranes from Sf9 cells expressing the beta 2AR and the beta 2AR/Galpha sbeta 1gamma 2,respectively) but did not influence the relative efficacy nor the potency of the three compounds tested (Table 1).

To test the effect of G protein coupling on the binding properties of these inverse agonists, saturation binding assays were carried out in membranes derived from cells expressing the receptor alone or in combination with Galpha sbeta 1gamma 2. As shown in Fig. 2 and Table 2, the apparent affinities of 125I-cyanopindolol, [3H]propranolol, and [3H]ICI 118551 for the beta 2AR were not affected by the coexpression with Galpha sbeta 1gamma 2, although a significant decrease in the Bmax values was observed for the three inverse agonists tested (Fig. 2 and Table 2). To further document this effect of the G protein expression on the apparent binding capacity of the receptor, a large number of binding experiments were carried out with saturating concentration of each of the ligands. Figure 3 summarizes the results obtained in 12 to 15 independent experiments. Not only was the decrease in Bmax promoted by the coexpression of Galpha sbeta 1gamma 2 found to be highly reproducible, but the extent of the reduction was proportional (r2 = 0.989) to the relative inverse efficacy of the ligand used in the binding assay (Fig. 3B).


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 2.   Saturation binding isotherms for 125I-cyanopindolol, [3H]propranolol, and [3H]ICI 118551. Membranes derived from Sf9 cells expressing the beta 2AR alone () or in combination with Galpha sbeta 1gamma 2 (open circle ) were incubated in the presence of increasing concentration of radioligand and the specific binding determined as described under Materials and Methods. The data represent mean values of triplicate determinations from a typical experiment. Saturation curves were fitted to a one-binding site model using a least-squares nonlinear regression analysis (GraphPad). Bmax and Kd values were derived for each individual experiment, and mean values of three to four independent experiments are summarized in Table 2.


                              
View this table:
[in this window]
[in a new window]
 
TABLE 2
Binding parameters of 125I-cyanopindolol, [3H]propranolol, and [3H]ICI 118551 derived from saturation experiments carried out in membranes expressing the beta 2AR alone or in combination with Galpha sbeta 1gamma 2

Kd and Bmax were determined as described under Materials and Methods. Data were analyzed using the curve-fitting software GraphPad-Prism. Values represent means ± S.E.M. of n independent experiments performed in triplicates.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of Galpha sbeta 1gamma 2 expression on the binding of [3H]ICI 118551, [3H]propranolol, and 125I-cyanopindolol to beta 2AR. Sf9 cells were infected with the beta 2AR encoding baculovirus alone or in combination with baculovirus encoding Galpha sbeta 1gamma 2. The number of binding sites detected by saturating concentrations of [3H]ICI 118551 (n = 12), [3H]propranolol (n = 12) and 125I-cyanopindolol (n = 15) were then assessed in membrane preparations by direct radioligand binding assays as described under Materials and Methods. A, data are expressed as picomoles of receptor per milligram of membrane protein. The numbers in brackets represent the percentage of loss of binding sites. B, correlation between the Einv values and the loss of binding sites detected by each ligand upon expression of the G protein subunits. Statistical significance of the differences were assessed using the paired two-tailed Student's t test; ***, p < 0.001.

The loss in binding sites observed did not result from a reduction in beta 2AR protein expression since an increase rather than a decrease in immunoreactive beta 2AR was observed upon coexpression with Galpha sbeta 1gamma 2 (Fig. 4). The increase in the amount of receptor protein detected most likely results from a stabilizing effect of the G protein. This effect cannot be attributed to a particularity of the N terminus myc epitope tag since similar results were obtained using an anti-beta 2AR antibody directed against the carboxyl tail of the receptor (Santa Cruz Biotechnology, Inc.). Indeed, both the 45- to 55-kDa bands corresponding to heterogeneously glycosylated monomeric forms of the receptor and the dimeric species observed at ~120 kDa were found to be increased using the two antibodies. The detection of a greater number of bands in the 45- to 55-kDa region when using the anti-beta 2AR could be due to the fact that the myc epitope is localized close to the N terminus glycosylation site where it may be partly masked by the carbohydrate moieties, whereas the anti-beta 2AR is directed against the C terminus of the receptor.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of Galpha sbeta 1gamma 2 expression on the level of beta 2AR protein detected by Western blot. Solubilized membrane proteins derived from Sf9 cells expressing myc-tagged beta 2AR alone or in combination with Galpha sbeta 1gamma 2 were resolved by SDS-PAGE, transferred to nitrocellulose, and probed with 9E10 anti-myc antibody or anti-beta 2AR antibody as described under Materials and Methods. A, 5 and 10 µg of protein were loaded for each condition. Numbers on the left indicate molecular weight of marker proteins. B, densitometric analysis of immunoreactive beta 2AR expressed as the percentage of the value observed in cells expressing the beta 2AR alone (control). Values represent the means ± S.E.M. of three independent experiments. Statistical significance of the differences were assessed using the paired two-tailed Student's t test; ***, p < 0.001.

The apparent contradiction between the loss of binding site and the increase in receptor protein suggests that only a fraction of the receptor population can bind the radioligands used in the assays. This proposition would be consistent with the idea that the increased expression of G proteins stabilizes a coupled/activated state of the receptor that has an affinity for the inverse agonists that is too low to be detected in the binding assay.

If the latter hypothesis is true, one would predict that promoting the uncoupling of the receptor from the G protein by adding guanine nucleotide in the binding assay would reduce the effect of the G protein overexpression. As can be seen in Fig. 5, the addition of Gpp(NH)p in the binding assay reduced the loss of binding sites detected with [3H]ICI 118551, [3H]propranolol, and 125I-cyanopindolol upon coexpression of Galpha sbeta 1gamma 2.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of Gpp(NH)p on inverse agonists binding. The number of binding sites detected by [3H]ICI 118551 (n = 6), [3H]propranolol (n = 5), and 125I-cyanopindolol (n = 6) was assessed in membranes derived from cells expressing the beta 2AR alone or in combination with Galpha sbeta 1gamma 2 in the presence or absence of 100 µM Gpp(NH)p as described under Materials and Methods. Data are expressed as the percentage of binding sites detected by each radioligand in membranes expressing the beta 2AR alone in the absence of Gpp(NH)p and represent the means ± S.E.M. of five to six independent experiments. The dotted line represents the number of sites detected in membrane expressing the beta 2AR alone. Statistical significance of the differences was assessed using the paired two-tailed Student's t test; ***, p < 0.001.

To test the specificity of the phenomenon, coexpression with another G protein that has been shown to interact with the beta 2AR, Gi (Daaka et al., 1997), and one that does not, Gq (Offermanns and Simon, 1995), was investigated. As for Galpha sbeta 1gamma 2, coexpression of the receptor with Galpha i1beta 1gamma 2 led to a significant reduction of the number of sites that were recognized by the three inverse agonists (Fig. 6A). In contrast, coexpression with Galpha qbeta 1gamma 2 was without effect. Since Galpha q could readily be detected by Western blot analysis (Fig. 6B), the data indicate that the effect of G proteins on inverse agonist binding is linked to their selectivity of coupling to the receptor. However, the similar effect observed for Galpha s and Galpha i cannot be interpreted as an equivalent affinity of the receptor for the two G proteins since their relative level of expression cannot be easily determined. Nevertheless, to determine whether the influence of the G proteins can be observed at physiological level of expression, the effect of uncoupling the G proteins from the receptor using either cholera (CTX) or pertussis (PTX) toxins was investigated in HEK293s cells stably expressing the beta 2AR. As shown in Fig. 6C, a significant increase in 125I-cyanopindolol binding capacity was observed upon treatment with both toxins indicating that coupling to the two G proteins occurs at endogenous level of expression and can influence receptor binding properties.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 6.   Effect of G protein expression on the binding of inverse agonists to the beta 2AR. A and B, Sf9 cells were infected with baculoviruses encoding the beta 2AR alone or in combination with viruses encoding Galpha sbeta 1gamma 2, Galpha i1beta 1gamma 2, or Galpha qbeta 1gamma 2. A, [3H]ICI 118551, [3H]propranolol, and 125I-cyanopindolol binding was assessed in membranes expressing the beta 2AR alone or in combination with the indicated G protein subunits. Data are expressed as percentage of binding sites detected in membranes expressing the beta 2AR alone and represent the means ± S.E.M. of four independent experiments for each radioligand. The dashed line represents the number of sites detected in membrane expressing the beta 2AR alone. Statistical significance of the differences were assessed using the paired two-tailed Student's t test; ***, p < 0.001. B, the expression of each of the alpha -subunits was assessed by Western blot analysis using selective antibodies (see Materials and Methods). The faints bands detected with the anti-Galpha s in cells transfected with either beta -galactosidase (beta Gal) or beta 2AR encoding viruses alone reflect the presence of endogenous long and short forms of the insect Galpha s. C, 125I-cyanopindolol binding was assessed in membrane preparation from HEK293s cells stably expressing the human beta 2AR that were treated with PTX (50 ng/ml, 16 h) or CTX (300 ng/ml, 24 h) or were untreated. Data are expressed as the percentage of binding sites detected by the radioligand in control membranes expressing the beta 2AR and represent the means ± S.E.M. of four independent experiments. Statistical significance of the differences were assessed using paired two-tailed Student's t test; *, p < 0.05; **, p < 0.01.

In an effort to determine which of the alpha -subunit, the beta gamma -dimer, or the heterotrimer is responsible for the reduction in binding sites detected by the inverse agonists, the number of receptors measured by 125I-cyanopindolol was assessed following coexpression with Galpha s, Gbeta 1gamma 2, or Galpha sbeta 1gamma 2. A significant reduction was observed in the three coexpression conditions (Fig. 7). However, the greatest reduction was seen upon coexpression with the heterotrimer, 43%, compared with 34% and 17% for coexpression with Galpha s and Gbeta 1gamma 2, respectively. Given that exogenous Galpha s and Gbeta 1gamma 2 can interact with the insect alpha s-like and beta gamma -subunits, these data suggests that interaction with the heterotrimer is most likely responsible for G protein effect on inverse agonist binding.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 7.   Effect of Galpha s, Gbeta 1gamma 2, and Galpha sbeta 1gamma 2 expression on 125I-cyanopindolol binding to the beta 2AR. 125I-Cyanopindolol binding was assessed in membranes expressing the beta 2AR alone or in combination with the indicated G protein subunits. Data are expressed as picomoles of receptor per milligram of membrane protein and represent the means ± S.E.M. of three independent experiments for each condition. Statistical significance of the differences were assessed using the paired two-tailed Student's t test; ***, p < 0.001.

If the assumption that the loss of inverse agonist binding sites results from a stabilization of the activated form of the receptor by the heterotrimeric G protein is correct, one could predict that mutations that lead to constitutive activation of the receptor should have similar effects. To test this hypothesis, 125I-cyanopindolol binding was assessed in cells expressing either the wild-type or the constitutively active beta 2AR (CAMbeta 2AR) in which L266, K267, H269, and L272 were replaced by S, R, K, and A that correspond to the homologous region of constitutively active alpha 1b adrenergic receptor (Cotecchia et al., 1990; Samama et al., 1993). When cells expressing identical amounts of either beta 2AR or CAMbeta 2AR protein, as assessed by FACS analysis (Fig. 8A), were tested for the number of 125I-cyanopindolol binding sites, a significantly lower number of sites were found for the CAMbeta 2AR (Fig. 8B). To confirm that the difference in radioligand binding did not result from a lower level of protein expression or greater degradation, Western blot analyses were carried out. Equivalent amounts of binding sites detected by 125I-cyanopindolol in membranes expressing the wild-type beta 2AR or the CAMbeta 2AR were resolved by electrophoresis and detected using an anti-beta 2AR antibody (Santa Cruz Biotechnology, Inc.). As shown in Fig. 8C, the total amount of beta 2AR immunoreactivity was 1.5-fold higher in membranes from Sf9 cells infected with the CAMbeta 2AR than those expressing the wild-type receptor, thus confirming that a significant proportion of the CAMbeta 2AR is unable to bind 125I-cyanopindolol.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 8.   Binding capacity of wild-type (WT) and constitutively activated mutant (CAM) beta 2AR. A, WT and CAMbeta 2AR total cell expression quantified by cytofluorometry (FACS) analysis as described under Materials and Methods. Data presented are typical of two independent experiments. B, binding assays using a saturating concentration of 125I-cyanopindolol were carried out in membranes derived from cells expressing WT or CAMbeta 2AR. Data are expressed as picomoles per milligram of protein and represent the means ± S.E.M. of five independent experiments for each of the receptor constructs. Statistical significance of the differences was assessed using the paired two-tailed Student's t test; ***, p < 0.001. C, solubilized membrane proteins derived from cells expressing WT or CAMbeta 2AR were resolved by SDS-PAGE, transferred to nitrocellulose, and probed with an antibody raised against the carboxyl-terminal tail of the beta 2AR as described under Materials and Methods. Thirty-four to 250 fmol of receptor detected by 125I-cyanopindolol was loaded for each construct.

To investigate whether CAMbeta 2AR coupling to Gs protein could further modify inverse agonist binding, the specific binding of 125I-cyanopindolol, [3H]propranolol, and [3H]ICI 118551 was assessed in membranes derived from Sf9 cells expressing the constitutively active receptor alone or in combination with Galpha sbeta 1gamma 2. As previously observed for the wild-type beta 2AR (Fig. 3A), the number of CAMbeta 2AR binding sites detected by the three radioligands tested was significantly reduced upon overexpression of Galpha s (Fig. 9), indicating that interaction with the G protein can further stabilize the CAMbeta 2AR into a conformation that is not recognized by the inverse agonists.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 9.   Effect of Galpha sbeta 1gamma 2 expression on the binding of [3H]ICI 118551, [3H]propranolol, and 125I-cyanopindolol to CAMbeta 2AR. Radioligand binding was carried out in membranes derived from cells expressing the CAMbeta 2AR alone or in combination with Galpha sbeta 1gamma 2 using saturating concentrations of the radioligands as described under Materials and Methods. Data are expressed as the percentage of binding sites detected in membranes expressing the CAMbeta 2AR alone and represent the means ± S.E.M. of five independent experiments for each radioligand. The dashed line represents the number of sites detected in membrane expressing the beta 2AR alone. Statistical significance of the differences was assessed using the paired two-tailed Student's t test; ***, p < 0.001.

    Discussion
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

The results of the present study demonstrate that overexpression of trimeric G proteins (Galpha sbeta 1gamma 2 or Galpha ibeta 1gamma 2) results in a significant decrease of the total number of beta 2AR sites detected by inverse agonists. This finding is consistent with two of the predictions made by allosteric models for receptor activation (such as the extended ternary and the cubic models): 1) inverse agonists bind preferentially to the inactive (R) form of the receptor and 2) the interaction of the receptor with its cognate G protein stabilize the active form (R*) at the expense of R (Lefkowitz et al., 1993; Samama et al., 1993; Bond et al., 1995; Kenakin, 1995; Leff, 1995; Leff and Scaramellini, 1998). Similarly, our observation that the extent of decrease in inverse agonist binding is directly correlated to the inverse efficacy of the ligand used is consistent with efficacy-related changes in ligand binding predicted by all of these models following changes in R/R* ratio. Indeed, the conceptual framework proposed by the latter suggests that relative efficacy results from the distinct preferences of the compounds for the active and inactive receptor conformers (Black and Shankley, 1995; Leff, 1995; Milligan et al., 1995). Thus our results suggest that it is by stabilizing R* that the overexpressed G proteins allosterically promote a reduction in inverse agonist binding. This hypothesis is further supported by the fact that the inverse agonist also showed reduced binding to the CAMbeta 2AR.

The effect of G protein overexpression on inverse agonist binding reflected the coupling selectivity of the beta 2AR since Galpha s and Galpha i, which are both known signaling partners of this receptor (Gilman, 1987; Kobilka, 1992; Crespo et al., 1995; Bogoyevitch et al., 1996; Daaka et al., 1997; Yamamoto et al., 1997), but not Galpha q, which cannot couple to beta 2AR (Offermanns and Simon, 1995), promoted the reduction in inverse agonist binding. The hypothesis that the reduction in binding capacity resulted from the functional coupling of the beta 2AR to its cognate G proteins is also supported by the effects of Gpp(NH)p. Indeed, the receptor-G protein uncoupling promoted by the addition of the nonhydrolysable nucleotide during the binding assay partially inhibited the effect of G protein overexpression on inverse agonist binding. Although similar effects were observed upon overexpression of Galpha i and Galpha s, no conclusion on the relative affinity of the receptor for the two G proteins can be drawn since no information is available on their relative level of expression. However, the observation that both PTX and CTX led to an increase of 125I-cyanopindolol binding capacity in HEK293s cells expressing endogenous levels of G proteins suggests that coupling to both Gi and Gs can occur at physiological level of G protein expression. These result also indicate that the influences of G protein on receptor isomerization are not limited to the insect system but can also be seen in mammalian cells expressing normal levels of G proteins. These results are entirely consistent with the observed reduction in 125I-cyanopindolol binding previously reported by Krumins et al. (1997) upon elevation of Galpha s expression using a dexamethasone-inducible promoter in S49 cells.

Although the maximal loss of inverse agonist binding observed in Sf9 cells was found upon overexpression of the Galpha sbeta 1gamma 2 complex, significant effect could also be observed when either alpha s or the beta 1gamma 2 dimer was expressed individually. This may indicate that interaction with each of the G protein components is sufficient to partially stabilize R*. Alternatively, association of the overexpressed mammalian subunits with their endogenous insect partners (Hepler et al., 1993; Butkerait et al., 1995; Richardson and Robishaw, 1999) may be responsible for the effects.

The observation that Galpha sbeta 1gamma 2 overexpression could further decrease the binding of inverse agonists to the CAMbeta 2AR suggests that the mutations do not irreversibly activate the receptor but rather shift the equilibrium toward R* and that further stabilization of the active conformer can still be achieved upon allosteric interactions with its cognate G proteins. This is consistent with the previous observation that inverse agonists can inhibit the spontaneous activity of CAMbeta 2AR (Samama et al., 1993; Milligan et al., 1997). Reduced binding capacity of CAMbeta 2AR when compared with beta 2AR was previously attributed to the greater instability of the constitutively active mutant (Samama et al., 1993; Gether et al., 1997). Although this aspect was not directly assessed in the present study, our data suggest that the reduced ability of R* to bind to inverse agonists may also contribute to the lower binding generally obtained with this construct.

The allosteric effect of G protein overexpression on the binding of inverse agonists can be considered as the mirror image of the loss of agonist binding observed in many studies upon addition of nucleotides that promote receptor-G protein uncoupling. However, in most cases, such uncoupling is accompanied by a reduction of the affinity and not a loss of binding sites for agonists (Kenakin, 1996). Such a change in affinity and not Bmax is in fact what the allosteric models based on ternary complex formation predict since R*G has a high affinity while R has a low affinity for agonists. Nevertheless, in a few cases, the nucleotide-promoted uncoupling leads to an apparent lost in agonist binding capacity (Bouaboula et al., 1997; Ohtaki et al., 1998). This could be interpreted as an indication that the low affinity state of the receptor for the agonist is too low for any binding to be detected under the experimental conditions used. A similar reasoning can be applied for the apparent loss of inverse agonist binding capacity observed in the present study following overexpression of the G proteins. In this situation, the low affinity state of the inverse agonists for the R*G forms of the receptor would be undetectable. The fact that the apparent loss of binding sites persists throughout the binding assay and that the inverse agonist is not able to convert the entire population of receptor into the inverse agonist-bound R form suggests that the conversion of at least a subpopulation of the receptors is occurring at a very slow rate. This may indicate that something is preventing the free and rapid isomerization between R*G and R. The excess in G protein itself could be responsible for this phenomenon as it could lock some R into the R*G form. Given that G proteins have been shown to be in large excess of receptors in several cell types (Alousi et al., 1991; Post et al., 1995; Milligan, 1996), it may not be surprising that we observed the phenomenon not only upon overexpression of Gi and Gs in Sf9 cells but also in mammalian HEK293s cells expressing endogenous levels of G proteins.

Although this is the first study systematically assessing the effect of the G protein overexpression on the direct binding properties of a radioligand series with various inverse efficacies, changes in both affinities and apparent Bmax linked to alterations in the coupling state of GPCRs have previously been reported for a few inverse agonists. For example, guanine nucleotides treatment of membranes derived from cells expressing the human cannabinoid receptor CB1 (Bouaboula et al., 1997), or the serotoninergic 5HT2C receptor (Barker et al., 1994; Westphal and Sanders-Bush, 1994) was found to increase the affinity and the number of binding sites detected by the inverse agonists [3H]SR141716A and [3H]mesulergine, respectively. [3H]Spiperone binding capacity to the 5HT1A receptor was also found to be increased upon GTP treatment (Sundaram et al., 1993). Also, increase Galpha s expression was associated with a reduction in 125I-cyanopindolol binding capacity (Krumins et al., 1997). More recently, overexpression of Galpha i1 and Galpha o led to a reduction of the affinity of the inverse agonist methiothepin for the 5HT5A receptor (Francken et al., 2000).

The good correlation between inverse efficacy and the loss of binding promoted by G protein overexpression observed in the present study clearly establishes that signaling efficacy and binding to specific states (R versus R*) of the receptor are intimately linked. These results also indicate that the ratio between R and R* is under the dual influence of ligand binding and G protein coupling. It is therefore the resultant of the interactions within the ternary complexes that will ultimately determine the affinity states, the proportion of receptor in each of the affinity states, and the signaling efficacy for a given ligand. Whether R and R* each represent a discrete conformation or rather collections of receptor states cannot be directly addressed here. However, the observation that in some studies (Westphal and Sanders-Bush, 1994; Bouaboula et al., 1997) guanine nucleotide can affect simultaneously the measured affinity and the apparent Bmax for inverse agonists suggest that more than two conformations are involved.

Our findings should also prove to be of practical importance when using radioligand binding assays to determine receptor number in various pathophysiological conditions. If, as it is often the case, the radioligands used have inverse efficacy, the conditions that modify the R and R* ratio could be erroneously interpreted as changes in the total receptor number. This is particularly important when considering that many pathological conditions are accompanied by alteration in G protein levels and thus could influence the R/R* equilibrium. For example, increased Galpha s and Galpha i levels reported in various cardiovascular diseases could be a contributing factor to the decrease in beta AR density often detected with radiolabeled inverse agonists in these conditions (Schotten et al., 2000). Although the extent to which the allosteric effect contributed to the observed results cannot be easily determined, the use of neutral antagonists (when available) rather than inverse agonists as tracers may prove to be better choices.

    Acknowledgments

We are grateful to Dr. Monique Lagacée and Dr. Peter Chidiac for critical reading of the manuscript.

    Footnotes

Received March 29, 2001; Accepted July 20, 2001

1 Present address: Biosignal Inc., 1744 William Street, Montréal, H3J 1R4 Canada.

Supported by fellowships from the Heart and Stroke Foundation of Canada (HSFC; to M.A.), the Medical Research Council of Canada (MRCC; to G.P.), and The Canadian Hypertension Society (to H.A.) and by grants from the MRCC and the HSFC.

Dr. Michel Bouvier, Department of Biochemistry, Universitu of Montreal, 2900 Edouard Montpetit, Rm. D-360, P.O. Box 6128, Succ. Center-ville-Montreal PQ, H3C 3J7 Canada. E-mail: bouvier{at}bcm.umontreal.ca

    Abbreviations

GPCRs, G protein-coupled receptors; beta 2AR, beta 2-adrenergic receptor; CAM, constitutively activated mutant; Sf9, Spodoptera frugiperda 9; G protein, guanine nucleotide-binding protein; Gpp(NH)p, guanylylimidodiphosphate; PBS, phosphate buffer saline; ICI 118551, erythro-DL-1-(7-methylindan-4,1-oxy)-3-isopropylaminobutan-2-ol; HEK, human embryonic kidney; PTX, pertussis toxin; CTX, cholera toxin; FACS, fluorescence-activated cell sorter; PAGE, polyacrylamide gel electrophoresis; m.o.i., multiplicity of infection.

    References
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References